The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback